Outcomes Articles

Can the Patient-Matched Implant Be Ready When the Surgeon Needs It?

October 26, 2026

About This Report

Featuring insights from Nancy Hairston, Anekant Jain, and Betsabeh Madani-Hermann hosted by our CEO, Saul Marquez.

Two weeks to mill a titanium plate, compared with printing several parts overnight. That contrast appears in the Outcomes Rocket conversation with Nancy Hairston, President and CEO of MedCAD. It makes the progress in patient-matched manufacturing tangible. It can also make a delivery promise sound simpler than it is.

The surgeon needs a coordinated case, not a finished print in isolation. Imaging, the surgical plan, guides and implants still have to agree. A faster machine does not settle which design has been approved, whether the other components are ready or what remains before release and delivery. The interview's printing comparison is not a complete imaging-to-surgery turnaround time.

For patient-specific device founders and operations leaders, the next commitment should therefore cover the whole case. Three separate interviews help test that promise: MedCAD makes the linked components visible, EOS supplies the manufacturing questions and Philips exposes the overlooked dependency. Before committing to a date, identify what must be ready together and which assumption could still change it.

Define the Whole Patient-Matched Case

At MedCAD, Nancy Hairston describes patient matching as developing a solution for one person at a time. The team uses CT scans and other imaging data to design around an individual's anatomy. That approach can be especially useful where small differences in bone structure or positioning affect the surgical plan. Nancy is careful to acknowledge that customization makes sense in some situations more than others.

Consider the foot and ankle systems she discusses. The implant works with a coordinated surgical plan and guides for precise bone preparation. Nancy also describes anatomical models that help surgeons understand the anatomy they're working with, illustrating another component of MedCAD's broader patient-matched approach. She describes implants designed to fit the patient's anatomy after the planned cuts, rather than requiring surgeons to bend a standard plate into position during the procedure.

That relationship between the components is important. A precisely manufactured implant offers limited value if the surgical guide reflects a different plan or the team hasn't confirmed how the components work together. The intended anatomy, planned preparation and implant design have to agree.

The overnight-printing comparison becomes useful once it sits inside that larger chain of work. Ask what is complete when the printer stops and what still needs attention. Design review, finishing, inspection, release and delivery can each affect the commitment. Their actual requirements and timing must be established for the product and case, not inferred from the machine's speed.

Map a representative case from initial imaging to the coordinated components required for delivery. Start with the approved surgical plan, then identify which guides and implants depend on it. If a plan changes, the team needs to know which linked work must be reconsidered. This is a coordination question to answer with clinical and quality owners, not a claim that a particular MedCAD case failed.

Those questions are an editorial coordination exercise, not a description of MedCAD's complete operating procedure. Actual clinical, quality and release requirements remain with the responsible teams.

Once the whole case is visible, the next question is whether the manufacturing assumptions can hold repeatedly.

Ask Whether Production Can Repeat the Result

Anekant Jain, Manager, Polymer Technologies at EOS, draws an important distinction between printing an object and manufacturing one reliably. Speaking with Saul Marquez on Outcomes Rocket, Anekant describes industrial additive manufacturing in terms of qualification, scalability, yield, turnaround and uptime. Those considerations become particularly relevant when a medical device manufacturer needs to make a dependable delivery commitment.

Qualification asks whether the intended process and output meet applicable requirements. Yield concerns how consistently production produces acceptable parts. Scalability raises questions about capacity as demand changes, while turnaround and uptime affect how predictably the work can be completed. A successful print alone doesn't answer those questions.

Anekant also discusses the expanding possibilities for customized implants and prosthetics. New materials and manufacturing techniques allow designers to explore solutions that conventional production methods might make difficult. But the ability to produce a customized shape, the ability to manufacture it consistently and the suitability of that design for its intended clinical application require different supporting evidence.

This distinction matters when reviewing a patient-matched case. The manufacturing team needs to understand the intended device, its materials and the production requirements that apply. Nothing in these separate interviews establishes that EOS and MedCAD use the same materials, equipment or qualification process. Their experiences illuminate different parts of the readiness problem without describing a shared implementation.

A practical review would ask manufacturing and quality leads to identify the evidence supporting acceptable output, the capacity available for the work and any outstanding qualification activities. Who owns those activities? Which assumptions have been checked against actual production capabilities? The appropriate acceptance criteria must come from the responsible product and quality teams, rather than a generic checklist.

Even a sound production plan can depend on work outside the machine and outside the immediate team's control.

Find the Dependency That Could Still Block Readiness

Betsabeh Madani-Hermann, Global Head of Research at Philips, describes a practice for identifying risks that enthusiastic project teams may overlook.

In Philips' exploratory innovation programs, teams conduct a premortem early in a project's life. They imagine the project has failed three years in the future, then work backward to identify what might have caused it. The exercise separates problems within the team's control from those requiring outside cooperation or preparation.

The Philips conversation gives that exercise an unexpectedly practical result: procurement became visible as a risk. An exploratory project might miss a milestone if something essential couldn't be purchased in time. Identifying that possibility brought relationships and education forward, before the team would normally have involved procurement. The account describes earlier preparation, not a measured delay avoided.

For a patient-matched surgical case, the same reasoning offers a useful coordination question. Which required approval, resource, supplier relationship or handoff is still being treated as an assumption? A team might have confidence in its design and manufacturing plan while remaining uncertain about another requirement affecting delivery.

Applying that question to a surgical case is an editorial synthesis, not a Philips delivery protocol. The case team should turn a plausible concern into a specific check: the approval still needed, the resource still unconfirmed or the handoff another person has not accepted. A vague worry does little to improve a date commitment.

Betsabeh also acknowledges a limitation of premortems. Preparation can reduce risk without eliminating it. Projects may still miss milestones, encounter unexpected findings or need to stop. Completing the exercise shouldn't create another unsupported promise of success.

The next commitment should rest on the complete case and its unresolved dependencies, not on the fastest stage in isolation.

Make the Case-Readiness Promise Explicit

Before committing to a delivery date, bring the case-planning owner, manufacturing lead, quality lead and delivery or procurement owner into one discussion. Include the clinical partner where appropriate. The goal is to establish what must be ready together and whether the proposed commitment accounts for the work still outstanding.

Create a case-readiness map with four entries for each component, approval and handoff:

Confirmed work: What is complete and what evidence supports that status.
Open assumption: What the delivery commitment still depends on.
Next owner: Who must supply the decision, component or confirmation.
Date consequence: Whether the unresolved dependency could change the commitment.

This is a proposed coordination exercise, not a clinical scheduling or release protocol. Existing clinical decisions, quality requirements and authorization processes still govern whether a solution is suitable and can be released.

If an essential dependency remains unresolved, assign an owner and determine what evidence or action is still needed. When that dependency prevents a supportable delivery commitment, revise the proposed date through the team's established decision process.

Printing multiple titanium parts overnight remains an important advance. The commercial promise becomes stronger when the team can show where that gain fits in a case timeline and what still governs delivery. That is what a clinical partner needs when planning around the commitment.

The printer's finish time matters. The promise belongs to the whole case.

About the Conversations

These are three separate Outcomes Rocket conversations, not a shared case study. During the time of recording, the guest names and titles were as follows: Nancy Hairston, President and CEO of MedCAD. Anekant Jain, Manager, Polymer Technologies at EOS. Betsabeh Madani-Hermann, Global Head of Research at Philips.